Hyderabad-based Indian maker of active pharmaceutical ingredients and intermediates, among the world's largest API producers, exporting to over 100 countries.
divislabs.comFounded
1990
Industry
Pharmaceuticals: active pharmaceutical ingredients (APIs) and intermediates
Headquarters
Divi Towers, Cyber Hills, Gachibowli, Hyderabad, Telangana 500032, India
Employees
Around 21,000 professionals plus 700 scientists
Revenue (FY25)
Rs 9,712 crore (about US$1.0 billion)Listed on
NSE: DIVISLAB, BSE: 532488
CEO
Dr. Kiran S. Divi
Chairman
Dr. Ramesh B.V. Nimmagadda
Legal name
Divi's Laboratories Limited (CIN L24110TG1990PLC011854)
Divi's Laboratories Limited is an Indian pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), intermediates, registered starting materials, and nutraceutical ingredients for the global pharmaceutical industry. It was founded by Dr. Murali Krishna Prasad Divi and incorporated on 12 October 1990. The company is headquartered at Divi Towers in Gachibowli, Hyderabad, Telangana, and ranks among the top three API manufacturers in the world.
The company runs its manufacturing from facilities in Telangana and Andhra Pradesh, including units near Choutuppal and Visakhapatnam, and exports to more than 100 countries. It employs around 21,000 professionals along with roughly 700 scientists. Its business covers generic APIs, custom synthesis for large pharmaceutical clients, and nutraceutical ingredients.
Divi's Laboratories is listed on the National Stock Exchange (DIVISLAB) and the Bombay Stock Exchange (532488). For the year ended 31 March 2025 it reported revenue of about Rs 9,712 crore, roughly US$1.0 billion. The company is led by Managing Director Dr. Murali K. Divi, CEO Dr. Kiran S. Divi, and Chairman Dr. Ramesh B.V. Nimmagadda, with Venkatesa Perumallu Pasumarthy as Chief Financial Officer.
Founder & Managing Director
Whole-Time Director & Chief Executive Officer
Non-Executive Chairman & Independent Director
Chief Financial Officer
Interview experience
6 out of 10
Interview difficulty
Medium
Interview process length
About a week
Practice real questions and get instant feedback before you walk in.
Q: What is the definition of calibration & verification?
A: Calibration compares an instrument's readings against a known reference standard and adjusts it to reduce error. Verification only checks whether the instrument still performs within accepted limits, without adjusting it.
Q: How to set the transformer differential relay?
A: You match the CT ratios and vector groups on both windings, then choose a pickup and bias slope so the relay ignores normal through-current and inrush but trips on internal faults.
Q: In 132 kv substation lightning arrestor (120 kv) connected to line, but line voltage comes to 132 kv, does it operate or not?
A: The 132 kV rating is line-to-line, so each phase sits at about 76 kV to ground, which a 120 kV rated arrester covers. It conducts only on transient surges, not on normal system voltage, so it won't operate just because the line reaches 132 kV.
Q: In 6.6 kv vacuum circuit breaker, vacuum bottle vacuum capacity?
A: A vacuum interrupter for a 6.6 kV breaker is sealed at a very high vacuum, typically around 10^-6 mbar (about 10^-4 torr or lower). That low pressure gives the fast dielectric recovery that quenches the arc.
Practice real questions and get instant feedback before you walk in.
Entry to experienced
₹12,00,000 to ₹17,00,000 per year (median ₹15,00,000)
6 salaries Salaries submitted
All-role average
₹4,33,096 per year
41 salaries Salaries submitted
Internship
₹20,000 to ₹25,000 per month
0 to 2 years
₹2,50,000 to ₹5,00,000 per year
FY25
₹88.2 crore total (fixed ₹29 lakh plus commission ₹87.9 crore)
FY2018-19 (dated)
About ₹30 crore per year
See how your pay compares and find roles that match your target.
Visakhapatnam (Chippada), Andhra Pradesh • Full-time (Trainee)
Kakinada, Andhra Pradesh • Apprenticeship / Trainee
Visakhapatnam (Chippada), Andhra Pradesh • Full-time (Trainee)
Hyderabad (Choutuppal / Unit I), Telangana • Full-time (Trainee)
Hyderabad (Choutuppal / Unit I), Telangana • Full-time (Trainee)
Kakinada, Andhra Pradesh • Apprenticeship / Trainee
Tailor your resume to each Divi's Laboratories role in minutes.
July 13, 2026
Divi's Laboratories recommends INR 30 final dividend for FY26
The board recommended a final dividend of INR 30 per equity share (face value INR 2) for the year ended March 31, 2026, with July 24, 2026 fixed as the record date and payout on or after August 14, 2026.
#dividend #FY26 #shareholderreturns
View postMay 25, 2026
Q4 FY26: revenue up 10%, custom synthesis strong but margins ease
Q4 FY26 net revenue rose about 10% YoY to roughly INR 2,830 crore, with custom synthesis up 18% and generic API down 3%. EBITDA grew 5% and margin held near 33%. Analysts flagged margin pressure but kept a positive medium-term view.
#Q4FY26 #results #customsynthesis
View postFebruary 11, 2026
Q3 FY26: revenue up 12% but profit dips on one-time labour-code charge
Q3 FY26 consolidated revenue grew 12.1% YoY to about INR 2,692 crore, while PAT slipped slightly to around INR 583 crore due to a one-time INR 74 crore employee-benefit charge from new labour codes. Nine-month PAT still rose to INR 1,817 crore.
#Q3FY26 #results #margins
View postNovember 7, 2025
Q2 FY26: record quarterly profit of INR 689 crore, up 35%
Divi's posted its highest quarterly profit in recent history at about INR 689 crore, up 35% YoY, on net sales of roughly INR 2,715 crore (up 16% YoY), with operating margin near 32.7% led by custom synthesis.
#Q2FY26 #results #recordprofit
View postAugust 6, 2025
Q1 FY26: net profit jumps 27% to INR 545 crore
Q1 FY26 consolidated net profit rose about 27% YoY to INR 545 crore on revenue of roughly INR 2,410 crore (up about 14% YoY), aided by custom synthesis growth and forex gains, though shares fell on the day.
#Q1FY26 #results #growth
View postIt manufactures active pharmaceutical ingredients (APIs), intermediates, registered starting materials, and nutraceutical ingredients for the global pharmaceutical industry, and it's among the top three API makers in the world.
